ArticleScientific reports2025
Cer(d18:1/16:0) as a biomarkers for acute coronary syndrome in Chinese populations.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lipid Cargo of Small Extracellular Vesicles as a Novel Contributor to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Comprehensive Lipidomic Profiling Reveals Distinct Metabolic Remodeling during Differentiation of Human Monocyte-Derived Macrophages.Journal of proteome research · 2026Article
- Associations of thyroid function, inflammatory cytokines, and ceramides with 30-day functional outcome after acute ischemic stroke.BMC neurology · 2026Article
- Diagnostic Potential of Metabolomic and Proteomic Biomarkers in Cardiology-A Narrative Review.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ceramides play a crucial role in atherosclerosis progression and have been linked to cardiovascular events. The objective of this study was to investigate the association between serum ceramide levels and Acute coronary syndrome, as well as evaluate their potential for predicting ACS in Chinese population. Data of 1327 patients with suspected or known coronary artery disease from Beijing anzhen Hospital and Handan First hospital were collected. Plasma ceramide were measured using the LC-MS/MS system. The area under the ROC curve was used to screen the most valuable predictor. Distinctive ACS-related variables were screened out using Boruta and LASSO regression. Multivariate Logistic models and restricted cubic spline analysis were conducted to examine the associations between Ceramide and ACS. Cer (d18:1/14:0), Cer (d18:1/16:0), Cer (d18:1/18:0), Cer (d18:1/20:0), Cer (d18:1/22:0), and Cer (d18:1/24:0) were significantly elevated in the ACS group. Diagnostic performance assessments showed that Cer(d18:1/16:0) had superior accuracy in detecting ACS compared to other ceramides tested. The Boruta algorithm identified 8 significant variables related to ACS. Cer(d18:1/16:0) associated with ACS were discovered using the LASSO logistic regression technique. Multivariate logistic regression models further supported the relationship between Cer(d18:1/16:0) and ACS. Additionally, a significant nonlinear relationship was observed between Cer(d18:1/16:0) and ACS, with a threshold of 150umol/L. The study found that ceramides, particularly Cer(d18:1/16:0), were significantly associated with ACS and could be a potential biomarker for predicting and diagnosing ACS in Chinese populations experiencing chest pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.